❤️ BSX $1.8M Long Call Bet — Whale Targets $60 by December on Farapulse + Watchman Recovery

Quick Take

A single institutional trader paid $1.8 million in premium at 12:59 ET on May 11 to open 3,800 December 18, 2026 $60 call contracts on Boston Scientific — a deliberate, out-of-the-money long call position with a breakeven nearly 21% above the current price. With BSX sitting near its 52-week low at $53.59, this is a textbook contrarian mean-reversion trade: the buyer is betting that the market has overpenalized BSX for a guidance cut that does not reflect the underlying strength of its Cardiovascular franchise.

The trade is not a close. It is not a hedge. Order_Type = BTO — the whale paid $4.95 per contract and opened a new directional long position with a defined, limited-downside profile. Maximum loss is capped at the $1.8M premium. Upside is uncapped above $64.95.

The thesis is straightforward: BSX traded between $95 and $109 as recently as late 2025. The stock has been cut roughly in half on a combination of guidance pressure and PFA competitive fear. With 9.4% Q1 organic growth, a 13.5% Cardiovascular beat, confirmed AVANT GUARD superiority data at HRS 2026, and a dense catalyst calendar through December, this buyer sees a setup where sentiment recovery — not a fundamental turnaround — is all that is required to put the $60 strike in play.

---

Company Overview

Boston Scientific (NYSE: BSX) is one of the world's largest pure-play medical device companies, with roughly $79.5B in market capitalization and over $21B in trailing revenue. The company operates across three segments — Cardiovascular, MedSurg, and Electrophysiology — with its highest-growth franchise concentrated in cardiac rhythm management.

Four products anchor the bull case:

• FARAPULSE PFA (Pulsed Field Ablation) — Boston Scientific's single-shot catheter system for atrial fibrillation ablation. FARAPULSE is the current market leader in next-generation PFA, with demonstrated superiority over anti-arrhythmic drugs in the AVANT GUARD trial presented at HRS 2026. Global adoption is in early innings; the worldwide AF ablation market represents a multi-billion-dollar opportunity.

• WATCHMAN FLX / WATCHMAN Elite — The company's left atrial appendage closure (LAAC) device franchise, the global leader in LAAC. WATCHMAN sales of $506M in Q1 2026 grew 19.2% year-over-year. A next-generation WATCHMAN Elite is in active development with H2 2026 launch discussions underway.

• AGENT DCB (Drug-Coated Balloon) — An FDA-approved drug-coated balloon for in-stent restenosis. Three-year AGENT IDE follow-up data was presented at CRT 2026, and CMS reassigned drug-coated balloon coverage effective January 1, 2026, providing a meaningful U.S. reimbursement tailwind.

• Diversified MedSurg base — Endoscopy, urology, and neuromodulation divisions provide durable mid-single-digit growth.

The stock's 52-week range runs from approximately $53.63 to $109.50. At $53.59, BSX is trading at the very bottom of that range, against a consensus analyst target of $85–$93 and a Street-high target of $128 from Leerink Partners.

---

The Trade

This single print crossed at 3,800 contracts against just 199 in open interest — a Vol/OI ratio of 19.1x, meaning this trade single-handedly expanded OI nearly twentyfold at this strike. That is not a hedger layering protection; it is a speculator opening a fresh, directional, conviction-sized long. At $4.95 per contract ($495 per lot), the all-in cost was approximately $1.881M.

The $60 strike sits roughly 12% above the current $53.59 spot price and 12.3% above the GEX-model price of $53.41. The December 18 expiration gives the position 221 days of runway — seven months of catalyst exposure spanning two earnings prints, three major cardiology conferences, and multiple device launch milestones.

---

Risk / Reward Profile

The long call structure defines the risk precisely, which is a key feature of this trade given the elevated uncertainty around BSX.

At expiration, breakeven requires BSX to recover from $53.59 to $64.95 — a $11.36 move. That looks large in isolation but represents less than a 40% retracement of the stock's YTD drawdown from the $109 highs. Against the consensus analyst target of $85–$93, even a partial sentiment recovery well short of prior highs puts this call well in the money.

Because the position is long premium only, the buyer has no margin exposure and no ability to lose more than the $1.8M paid. This structure is appropriate for the elevated uncertainty environment around BSX.

---

Greeks Analysis

These estimates are approximations based on typical parameters for a 7-month, ~12% OTM call on a large-cap healthcare name with elevated implied volatility after a guidance cut. They are intended to orient the reader on risk dynamics, not substitute for live market quotes.

Key Greek dynamics to monitor:

Theta is the primary headwind. At 221 days, the daily decay is manageable relative to the position size, but if BSX grinds sideways for 60–90 days without a catalyst, premium erosion becomes meaningful. The position needs either price appreciation or an IV expansion event (such as a positive clinical data surprise) to offset time decay.

Vega is a double-edged consideration. After the April 22 guidance cut, BSX implied volatility is likely elevated relative to its historical norm. If the stock stabilizes and fear subsides without a bullish catalyst, IV compression could hurt the position even if the stock drifts modestly higher. The ideal scenario is a sharp upward repricing on a catalyst event — earnings, conference data, or an analyst upgrade cycle — which would deliver both delta gain and vega expansion simultaneously.

---

Gamma / Support and Resistance

GEX (Gamma Exposure) data as of May 11, 2026, with spot at $53.41:

The GEX model identifies the following key levels:

Support Levels (dominant put gamma):

• $53 — Strongest near-term support. Net GEX of -0.224, total GEX 0.307. This strike sits 0.77% below spot and represents where market makers are net short gamma on puts — meaning dealer hedging flows reinforce this level. BSX hovering just above $53 suggests the market is currently pinned to this support zone.
• $50 — Secondary structural support. Net GEX of -2.639, the highest absolute put-gamma cluster below spot. A break of $53 would likely test this level as dealer delta-hedging accelerates on the downside.
• $45 — Deep structural support. Relevant only in a scenario where the competitive narrative deteriorates sharply.

Resistance Levels (call/put gamma clusters above spot):

• $54 — Immediate resistance. 1.1% above spot; mixed call/put gamma. The first meaningful dealer overhead level.
• $55 — Key resistance cluster. Net GEX of -3.503 (total 5.195), the largest near-term resistance zone. Market makers are net short gamma at $55, creating friction as price approaches. A clean close above $55 on volume would be technically constructive.
• $60 — The target strike. Total GEX 4.594 with near-equal call and put positioning. This strike is a major gamma magnet — if BSX moves toward $60 ahead of expiration, dealer hedging flows will accelerate, potentially amplifying the move. Notably, this is exactly where the whale has positioned.

The GEX summary shows net_gex_bias = Bullish at current spot, meaning aggregate call gamma exceeds put gamma across the surface — a mild structural tailwind for upside moves.

---

YTD Chart

BSX has declined approximately 37% year-to-date, falling from the $85–$109 range in late 2025 to a 52-week low near $53.59 in May 2026. The April 22 Q1 earnings report and guidance cut marked the most recent leg lower. At current prices, the stock has priced in a significant deceleration scenario. The whale's entry at this level reflects a view that the post-earnings flush has created an asymmetric entry point.

---

Implied Move

The implied move chart reflects the options market's current expectation for BSX price distribution over the remaining life of the position. With the stock near its 52-week low and IV elevated post-earnings, the distribution is wide: the market is pricing a broad range of outcomes, consistent with a stock carrying both significant recovery potential and meaningful downside risk from competitive deterioration.

Several observations on the implied move context:

• IV is elevated vs. historical norms. Post-earnings IV spikes on guidance cuts typically produce a 10–20% IV premium over trailing 30-day realized volatility. A buyer entering here is paying above-average premium but also securing exposure at an inflection point where the risk/reward is arguably skewed to the upside.

• The $60 strike is within the implied distribution. While 21% above spot seems like a large move requirement, seven months of premium exposure across multiple binary events (Q2 earnings, ESC data, PERSIGMA reads) creates discrete jump scenarios. Each positive catalyst could independently move BSX 5–10%, and a compounding sequence could place $64.95 within reach without requiring a return to prior highs.

• Downside distribution is anchored by GEX support. The $53 put-gamma cluster and the deeper $50 structural support level, as identified in the GEX model, suggest the downside distribution is partially bounded by dealer hedging flows. This does not eliminate downside risk but implies the stock is not in free fall — market structure is providing a floor near current levels.

---

Scenario Analysis

The following table illustrates approximate December 18, 2026 expiration outcomes at various BSX price targets. Premium of $4.95 per contract is assumed as cost basis.

The scenario table illustrates the binary nature of long OTM options: the position loses the entire $1.881M in a wide range of outcomes (any close below $60 at expiry). However, upside convexity is substantial — a move to consensus targets in the $85–$93 range would generate a 5–6x return on the premium paid.

---

Catalysts

The December 18 expiration was not chosen arbitrarily. It provides exposure to a dense and specific sequence of catalysts that the buyer appears to be targeting.

Q1 2026 Results — The Setup (April 22, 2026)

Boston Scientific reported Q1 2026 sales of $5.203B with organic revenue growth of 9.4%. The Cardiovascular segment delivered $3.503B (+13.5%), anchored by FARAPULSE and WATCHMAN. Adjusted EPS grew 6%. The stock sold off sharply because management cut FY2026 reported sales growth guidance to 7.0%–8.5% and Q2 to 5.5%–7.5%, citing PFA competitive pressure and WATCHMAN volume softness. CEO Mike Mahoney flagged WATCHMAN sales of $506M as below internal expectations, even though the segment grew 19.2% year-over-year.

The key takeaway for contrarians: the guidance cut was driven by near-term volume headwinds, not structural franchise deterioration. The stock's 37% YTD decline appears to be pricing in a much worse scenario than the actual results suggest.

HRS 2026 — AVANT GUARD Superiority Data (April 24–26, 2026, Chicago)

Just two days after the earnings-driven selloff, Boston Scientific presented AVANT GUARD trial data at Heart Rhythm 2026 demonstrating statistical superiority of FARAPULSE PFA over anti-arrhythmic drug therapy for atrial fibrillation. Persistent-AF FARAPULSE efficacy was confirmed at approximately 65%, reinforcing the device's differentiation versus both drug therapy and older ablation modalities. The conference also featured WATCHMAN FLX Pro presentations and early pipeline data on the WATCHMAN Elite next-gen device. This data largely failed to move the stock in the face of post-earnings selling — which is precisely the type of disconnect that contrarian buyers look to exploit.

AGENT DCB — CMS Reimbursement Tailwind (Active)

Three-year AGENT IDE follow-up data was presented at CRT 2026, and CMS reassigned drug-coated balloon reimbursement coverage effective January 1, 2026. This reimbursement change is a structural volume tailwind for AGENT DCB in U.S. hospitals treating in-stent restenosis — a headcount that is large, underserved, and now better covered. The financial contribution is gradual but real and should begin appearing in quarterly volume figures from Q2 2026 onward.

Q2 2026 Earnings — July 29, 2026 (Key Event)

The first major catalyst in the window is the July 29 Q2 print. This is the first opportunity for management to demonstrate whether the guidance cut was conservative or the beginning of a more sustained deceleration. The key metrics to watch: WATCHMAN U.S. volume recovery, FARAPULSE unit placements versus J&J Varipulse, and any update on AGENT DCB ramp trajectory. Consensus EPS estimate is $0.82–$0.84. A beat-and-raise scenario — even a modest one — could be the inflection point that resets the multiple from current depressed levels.

ESC Congress 2026 — August 28 to September 1, Madrid

The European Society of Cardiology Congress is a major venue for cardiovascular device data. Boston Scientific is expected to present expanded FARAPULSE efficacy data, potentially including persistent AF labeling expansion updates and broader outcomes from concomitant LAAC + PFA procedures. Positive European data readouts at ESC have historically driven re-rating events in BSX given the scale of the European EP market.

TCT 2026 — October

Transcatheter Cardiovascular Therapeutics is the key venue for AGENT DCB long-term outcomes and peripheral intervention pipeline data. Three-year data will likely be supplemented by early enrollment updates on the five-year AGENT follow-up and any new ISR procedural volume data following the CMS coverage expansion.

PERSIGMA Trial — J&J Head-to-Head (Ongoing Risk / Catalyst)

Johnson & Johnson has initiated the PERSIGMA RCT, a head-to-head comparison of Varipulse Pro versus FARAPULSE in 466 patients. This 466-patient trial is a multi-year catalyst with early procedural data potentially emerging in H2 2026. Favorable reads for FARAPULSE would be a significant positive catalyst. Unfavorable early reads would represent the primary downside scenario for this options position. The market has partially priced in competitive risk following J&J's report of 12.6% EP growth in Q1 2026 attributed in part to Varipulse, which means a neutral-to-positive PERSIGMA read would represent an incremental positive surprise.

Analyst Consensus

Piper Sandler reiterated Buy on May 4, 2026. Canaccord Genuity cut its target to $71 on April 23 following the guidance reduction. Leerink Partners maintains the Street-high $128 target. Consensus across 33 analysts sits at Strong Buy with 31 buys, 2 holds, and zero sells, average target approximately $85–$93. At $53.59, BSX trades at a roughly 37–43% discount to consensus targets.

---

Three Trading Ideas

These are structured approaches to the BSX setup at various risk appetites. They are provided for educational and analytical purposes, not as specific investment advice.

1. Replicate the Whale — Outright Long Call (Higher Risk, Higher Reward)

Buy the December 18, 2026 $60 call at approximately $4.95 per contract. This is the exact trade the institutional buyer executed. The position has a defined $495 maximum loss per contract, a breakeven at $64.95, and unlimited upside exposure through the December expiry. This structure is appropriate for a speculator who shares the contrarian view and wants full upside participation with capped downside. Position sizing should reflect that a 100% loss of premium is a realistic outcome if BSX fails to recover from its 52-week low.

Key watch dates: July 29 Q2 earnings, ESC August 28 — September 1, and any PERSIGMA procedural data announcements.

2. Bull Call Spread — Reduce Premium Cost, Cap Upside

Buy the December 18, 2026 $60 call and simultaneously sell the December 18, 2026 $70 call. This structure reduces the net debit paid while sacrificing upside above $70. The $70 target is roughly 30.6% above spot and represents approximately 75% of the move toward consensus analyst targets. If the goal is probability-weighted return rather than uncapped optionality, the spread captures most of the recovery thesis at lower premium cost.

Approximate structure: $60/$70 call spread at an estimated net debit of $2.50–$3.00, maximum gain approximately $7.00–$7.50 per spread ($700–$750 per contract), breakeven approximately $62.50–$63.00.

3. Wait for a Catalyst Trigger — Reduce Time Decay Risk

Rather than entering at current IV levels, a patient buyer could wait for the July 29 Q2 report and enter calls on a positive reaction, accepting a higher stock price but purchasing options with 5 months remaining at potentially lower IV (if the report reduces uncertainty). This approach sacrifices some of the current mean-reversion entry but reduces the risk that 3–4 months of time decay erodes the position before a meaningful catalyst materializes.

This is particularly relevant given that BSX is showing no immediate technical catalysts and the GEX data shows $55 as a significant overhead resistance — a level the stock would need to clear before the $60 strike becomes a realistic near-term target.

---

Risk Factors

Any holder of this position or similar exposure should actively monitor the following:

J&J Varipulse Pro Competition. This is the primary fundamental risk. J&J attributed 12.6% EP segment growth in Q1 2026 to Varipulse momentum and has announced the PERSIGMA head-to-head trial. If early procedural data or real-world volume trends indicate Varipulse is capturing FARAPULSE share faster than management's guidance assumed, sentiment could deteriorate further before the December expiry.

Second FY2026 Guidance Cut. Management already cut guidance once in April. A second downward revision at the Q2 print on July 29 would signal either that competitive pressure is more severe or that execution issues exist independent of competition. The options market would likely reprice lower on such an event, and the December $60 call could lose significant value on both delta decline and potential IV collapse following the event.

AGENT IDE Long-Term Outcomes. While three-year data was positive at CRT 2026, any unfavorable five-year outcome data from AGENT follow-up studies could slow DCB adoption — one of the key near-term volume growth drivers.

FDA and Regulatory Timing. WATCHMAN Elite and next-generation FARAPULSE indication expansions depend on FDA approval timelines. Regulatory delays push out the revenue inflection point.

Macro and Hospital Capex. BSX has significant exposure to hospital capital budgets and elective procedure volumes. Any deterioration in hospital spending — driven by budget pressures, staffing constraints, or a broader healthcare reimbursement revision — would weigh on procedural volumes across FARAPULSE, WATCHMAN, and AGENT DCB simultaneously.

Implied Volatility Compression. With BSX near its 52-week low and IV elevated post-earnings, a return to normalcy — even without a negative catalyst — could compress the premium on the December $60 calls as fear subsides. Buyers of premium near peak IV should account for this scenario explicitly.

---

Bottom Line

A single buyer spent $1.8 million to own December $60 calls on Boston Scientific when the stock sits near a multi-year low. The structure is clean: BTO, long call, maximum loss capped at the premium paid, and 221 days of catalyst-dense runway ahead.

The thesis is not that BSX will return to its $109 highs by December. It is that the market has over-rotated following a guidance cut that was driven by near-term competitive dynamics — not by a structural impairment of the company's dominant Cardiovascular franchise. A 9.4% organic growth rate, $3.5B Cardiovascular quarterly revenue, confirmed FARAPULSE superiority data, and a WATCHMAN franchise growing 19% annually do not describe a broken business.

The $60 strike requires a roughly 12% move from current spot — and the options position profits from any close above $64.95 at expiration, a 21% move. Against a consensus analyst target of $85–$93, and with multiple catalysts concentrated in a 7-month window, the whale is betting that gravity eventually reasserts itself.

The risks are real: J&J's Varipulse is a legitimate competitive threat, guidance credibility is impaired, and this is a long-premium bet in an elevated IV environment. But for a trader with a multi-month time horizon and a contrarian view on BSX's selloff, the structure is well-designed. Risk is defined. Time is ample. The catalyst calendar is loaded.

---

Disclaimer

This analysis is provided for informational and educational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Options trading involves substantial risk of loss and is not appropriate for all investors. The potential for total loss of premium paid is a realistic outcome for any long options position. Past performance of similar trades does not guarantee future results. Greeks and probability estimates in this article are approximations based on market norms and are not sourced from a live pricing model; actual values will differ. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions. The author may or may not hold positions in the securities discussed.

Published: May 11, 2026.